The Strategic Focus of Roche-Genentech on Personal Genetic data

03/04/2015 - 4 minutes

Personal Genetic data plays more and more a critical role in drug development. Major Pharma company Roche and its Biotech subsidiary Genentech are iconic in this trend. They have always been the first ones to catch up the wave and get profit from it. Today, Genentech believes and focus on genome sequencing to continue bringing breakthrough treatments to patients, and  generating value by doing so.

Roche-Genentech were pioneer in using biomarkers and diagnostics and Herceptin is a perfect example of it. It is a breast cancer treatment which works only for patients that are positive to the biomarker HER2. It allows the treatment to segmented patient population and offers a more effective treatment. Successful treatments for HER2-positive women went from nearly 20% to nearly 70%, mainly thanks to this drug in a period of 10 years. It was a big therapeutical success and a big commercial achievement.

Genentech and Roche now believe that genome sequencing and its analysis will lead to the discovery and development of new diagnostic tests and new therapeutics.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member